Imarikiren (development code: SCO-272), a direct renin inhibitor, is expected to control blood pressure by inhibiting the renin-angiotensin-aldosterone system (RAAS) and manage various diseases caused by RAAS. The Phase 2b study of Imarikiren had been completed with positive results.

Indication

  • Diabetic kidney disease
  • Hypertension
  • Change
  • Activation
  • Benefits
  • Inhibition
Angiotensinogen
Angiotensin Ⅰ
Angiotensin Ⅱ
ACE inhibitors
ACE
SCO-272
Renin
AT1 receptor
ARB
Hypertension

Hypertension

Renal dysfunction

Renal dysfunction

Heart failure

Heart failure

ACE : Angiotensin-converting enzyme

ARB : Angiotensin receptor blocker

Renin is an enzyme that converts angiotensinogen into angiotensin I. When angiotensin I is further converted to angiotensin II and acts on an AT1 receptor, it causes hypertension, renal disease, and heart failure. By inhibiting the action of renin, which is the root of these sequential reactions, SCO-272 is expected to exert different beneficial effects to existing drugs, such as ACE inhibitors and ARB that inhibit the secondary reaction.